146 related articles for article (PubMed ID: 32960421)
1. Determination of risk factors for progression in patients with viable tumor at post-chemotherapy lymph node dissection due to disseminated non-seminomatous germ-cell tumors.
Altan M; Haberal HB; Aşçı A; Güdeloğlu A; Doğrul AB; Yazıcı MS; Akdoğan B; Özen H
Int J Clin Oncol; 2021 Jan; 26(1):186-191. PubMed ID: 32960421
[TBL] [Abstract][Full Text] [Related]
2. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
[No Abstract] [Full Text] [Related]
3. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?
Spiess PE; Tannir NM; Tu SM; Brown GA; Liu P; Kamat AM; Wood CG; Evans JG; Pisters LL
Cancer; 2007 Dec; 110(12):2700-8. PubMed ID: 17948916
[TBL] [Abstract][Full Text] [Related]
4. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
[TBL] [Abstract][Full Text] [Related]
5. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?
Spiess PE; Brown GA; Pisters LL; Liu P; Tu SM; Evans JG; Kamat AM; Black P; Tannir NM
Cancer; 2006 Oct; 107(7):1503-10. PubMed ID: 16944534
[TBL] [Abstract][Full Text] [Related]
6. Retroperitoneal lymph node dissection as adjuvant therapy in the treatment of non-seminomatous testicular cancer.
Thijssens K; Vaneerdeweg W; Schrijvers D; Eyskens E; Van Oosterom A
Acta Chir Belg; 2003; 103(6):599-602. PubMed ID: 14743567
[TBL] [Abstract][Full Text] [Related]
7. Post-chemotherapy laparoscopic retroperitoneal lymph node dissection is feasible for stage IIA/B non-seminoma germ cell tumors.
Nakamura T; Kawauchi A; Oishi M; Ueda T; Shiraishi T; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Clin Oncol; 2016 Aug; 21(4):791-795. PubMed ID: 26701172
[TBL] [Abstract][Full Text] [Related]
8. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
[TBL] [Abstract][Full Text] [Related]
9. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors].
Liu ZW; Zhou FJ; Han H; Qin ZK; Yu SL; Li YH; Ye YL; Teng XY
Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998
[TBL] [Abstract][Full Text] [Related]
10. Retroperitoneal lymph node dissection for residual masses after chemotherapy in nonseminomatous germ cell testicular tumor.
Luz MA; Kotb AF; Aldousari S; Brimo F; Tanguay S; Kassouf W; Aprikian AG
World J Surg Oncol; 2010 Nov; 8():97. PubMed ID: 21062470
[TBL] [Abstract][Full Text] [Related]
11. Long-term oncological outcome after post-chemotherapy retroperitoneal lymph node dissection in men with metastatic nonseminomatous germ cell tumour.
Fléchon A; Tavernier E; Boyle H; Meeus P; Rivoire M; Droz JP
BJU Int; 2010 Sep; 106(6):779-85. PubMed ID: 20089110
[TBL] [Abstract][Full Text] [Related]
12. Lymph Node Yield in Primary Retroperitoneal Lymph Node Dissection for Nonseminoma Germ Cell Tumors.
Nayan M; Jewett MA; Sweet J; Anson-Cartwright L; Bedard PL; Moore M; Chung P; Warde P; Hamilton RJ
J Urol; 2015 Aug; 194(2):386-91. PubMed ID: 25823792
[TBL] [Abstract][Full Text] [Related]
13. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis.
Nitta S; Kawai K; Kimura T; Kandori S; Kawahara T; Kojima T; Nishiyama H
Int J Urol; 2021 Aug; 28(8):840-847. PubMed ID: 34085325
[TBL] [Abstract][Full Text] [Related]
14. Midline Extraperitoneal Approach to Retroperitoneal Lymph Node Dissection in Testicular Cancer: Minimizing Surgical Morbidity.
Syan-Bhanvadia S; Bazargani ST; Clifford TG; Cai J; Miranda G; Daneshmand S
Eur Urol; 2017 Nov; 72(5):814-820. PubMed ID: 28325537
[TBL] [Abstract][Full Text] [Related]
15. Risk Factors for Relapse in Nonseminomatous Testicular Cancer After Postchemotherapy Retroperitoneal Lymph Node Dissection With Viable Residual Cancer.
Antonelli L; Ardizzone D; Tachibana I; Adra N; Cary C; Hugar L; Sexton WJ; Bagrodia A; Mego M; Daneshmand S; Nicolai N; Nazzani S; Giannatempo P; Franza A; Heidenreich A; Paffenholz P; Saoud R; Eggener S; Ho M; Oswald N; Olson K; Tryakin A; Fedyanin M; Naoun N; Javaud C; Cazzaniga W; Nicol D; Gerdtsson A; Tandstad T; Fizazi K; Fankhauser CD;
J Clin Oncol; 2023 Dec; 41(34):5296-5305. PubMed ID: 37656935
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
[TBL] [Abstract][Full Text] [Related]
17. Perioperative complications and oncological outcomes of post-chemotherapy retroperitoneal lymph node dissection in patients with germ cell cancer at two high-volume university centres in Switzerland - a retrospective chart review.
Notarfrancesco M; Fankhauser CD; Lorch A; Ardizzone D; Helnwein S; Hoch D; Hermanns T; Thalmann G; Beyer J
Swiss Med Wkly; 2023 Apr; 153():40053. PubMed ID: 37080191
[TBL] [Abstract][Full Text] [Related]
18. Laparoscopic Postchemotherapy Retroperitoneal Lymph-Node Dissection Can Be a Standard Option in Defined Nonseminomatous Germ Cell Tumor Patients.
Nicolai N; Cattaneo F; Biasoni D; Catanzaro M; Torelli T; Zazzara M; Necchi A; Giannatempo P; Raggi D; Piva L; Colecchia M; Salvioni R; Stagni S
J Endourol; 2016 Oct; 30(10):1112-1119. PubMed ID: 27533924
[TBL] [Abstract][Full Text] [Related]
19. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection.
Spiess PE; Tannir NM; Brown GA; Liu P; Tu SM; Evans JG; Pisters LL
Urology; 2007 Dec; 70(6):1173-8. PubMed ID: 18158041
[TBL] [Abstract][Full Text] [Related]
20. Post-Chemotherapy Robotic Retroperitoneal Lymph Node Dissection: Institutional Experience.
Kamel MH; Littlejohn N; Cox M; Eltahawy EA; Davis R
J Endourol; 2016 May; 30(5):510-9. PubMed ID: 26669219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
